Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Leonidas ChouliarasAlan ThomasMaura MalpettiPaul DonaghyJoseph KaneElijah MakGeorge SavulichMaria A Prats-SedanoAmanda J HeslegraveHenrik ZetterbergLi SuJames Benedict RoweJohn Tiernan O'BrienPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
This large study shows the role of plasma biomarkers in differentiating patients with different dementias, and at monitoring longitudinal change. We confirm that p-tau181 is elevated in MCI+AD, versus controls, FTD and PSP, but is less accurate in the classification between MCI+AD and LBD or detecting amyloid brain pathology in LBD. NfL was elevated in all dementia groups, while GFAP was elevated in MCI+AD and LBD.